The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.
 
Deepak Kilari
Honoraria - Exelixis
Consulting or Advisory Role - Exelixis; Merck Sharp & Dohme; Myovant Sciences; Sanofi
Speakers' Bureau - Astellas Pharma; Exelixis; Genzyme; Genzyme (Inst); Janssen
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Genentech (Inst)
Travel, Accommodations, Expenses - Bayer; Clovis Oncology; Exelixis; Janssen; Sanofi
 
Aniko Szabo
No Relationships to Disclose
 
Kathryn A. Bylow
No Relationships to Disclose
 
Robert S. Alter
Consulting or Advisory Role - Bayer; Eisai; EMD Serono; Janssen Biotech
Speakers' Bureau - Astellas Pharma; Bayer; Janssen Oncology; Pfizer
 
Ariel Ann Nelson
No Relationships to Disclose
 
Emily Lemke
Honoraria - Medscape
Consulting or Advisory Role - Axdev
 
William Adrian Hall
Research Funding - Elekta (Inst)
Travel, Accommodations, Expenses - Elekta (Inst)
 
Scott Johnson
No Relationships to Disclose
 
Peter Langenstroer
No Relationships to Disclose
 
Kenneth Jacobsohn
No Relationships to Disclose
 
Nancy B. Davis
Consulting or Advisory Role - Janssen Biotech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Seattle Genetics/Astellas (Inst); Taris BioMedical (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Jounce Therapeutics; Taris BioMedical
 
Chunkit Fung
Consulting or Advisory Role - Exelixis; Novartis; Novartis
Research Funding - Astellas Pharma (Inst)
 
Matthew I. Milowsky
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Syndax (Inst)